Summary | |
---|---|
Symbol | CDKN2A |
Name | cyclin-dependent kinase inhibitor 2A |
Aliases | p16; INK4a; CMM2; ARF; INK4; p16INK4a; p19Arf; p14ARF; cyclin-dependent kinase inhibitor 2A (melanoma, p16, ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm Nucleus |
Domain | - |
Function |
Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. |
Biological Process |
GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000082 G1/S transition of mitotic cell cycle GO:0001558 regulation of cell growth GO:0001933 negative regulation of protein phosphorylation GO:0001952 regulation of cell-matrix adhesion GO:0001953 negative regulation of cell-matrix adhesion GO:0006323 DNA packaging GO:0006333 chromatin assembly or disassembly GO:0006338 chromatin remodeling GO:0006469 negative regulation of protein kinase activity GO:0006925 inflammatory cell apoptotic process GO:0007050 cell cycle arrest GO:0007160 cell-matrix adhesion GO:0007162 negative regulation of cell adhesion GO:0007265 Ras protein signal transduction GO:0007568 aging GO:0007569 cell aging GO:0010657 muscle cell apoptotic process GO:0010660 regulation of muscle cell apoptotic process GO:0010661 positive regulation of muscle cell apoptotic process GO:0010810 regulation of cell-substrate adhesion GO:0010812 negative regulation of cell-substrate adhesion GO:0016049 cell growth GO:0030308 negative regulation of cell growth GO:0031497 chromatin assembly GO:0031507 heterochromatin assembly GO:0031589 cell-substrate adhesion GO:0032088 negative regulation of NF-kappaB transcription factor activity GO:0033028 myeloid cell apoptotic process GO:0033032 regulation of myeloid cell apoptotic process GO:0033034 positive regulation of myeloid cell apoptotic process GO:0033673 negative regulation of kinase activity GO:0034390 smooth muscle cell apoptotic process GO:0034391 regulation of smooth muscle cell apoptotic process GO:0034393 positive regulation of smooth muscle cell apoptotic process GO:0035986 senescence-associated heterochromatin focus assembly GO:0042326 negative regulation of phosphorylation GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044843 cell cycle G1/S phase transition GO:0045736 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045786 negative regulation of cell cycle GO:0045926 negative regulation of growth GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051348 negative regulation of transferase activity GO:0070828 heterochromatin organization GO:0071103 DNA conformation change GO:0071887 leukocyte apoptotic process GO:0071888 macrophage apoptotic process GO:0071900 regulation of protein serine/threonine kinase activity GO:0071901 negative regulation of protein serine/threonine kinase activity GO:0090342 regulation of cell aging GO:0090343 positive regulation of cell aging GO:0090398 cellular senescence GO:0090399 replicative senescence GO:1904029 regulation of cyclin-dependent protein kinase activity GO:1904030 negative regulation of cyclin-dependent protein kinase activity GO:2000106 regulation of leukocyte apoptotic process GO:2000108 positive regulation of leukocyte apoptotic process GO:2000109 regulation of macrophage apoptotic process GO:2000111 positive regulation of macrophage apoptotic process GO:2000772 regulation of cellular senescence GO:2000774 positive regulation of cellular senescence |
Molecular Function |
GO:0004857 enzyme inhibitor activity GO:0004860 protein kinase inhibitor activity GO:0004861 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0008134 transcription factor binding GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity GO:0019207 kinase regulator activity GO:0019210 kinase inhibitor activity GO:0019887 protein kinase regulator activity GO:0030291 protein serine/threonine kinase inhibitor activity GO:0051059 NF-kappaB binding |
Cellular Component |
GO:0000785 chromatin GO:0000792 heterochromatin GO:0035985 senescence-associated heterochromatin focus |
KEGG |
hsa04110 Cell cycle hsa04115 p53 signaling pathway |
Reactome |
R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-2559583: Cellular Senescence R-HSA-2262752: Cellular responses to stress R-HSA-69231: Cyclin D associated events in G1 R-HSA-69236: G1 Phase R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-392499: Metabolism of proteins R-HSA-453279: Mitotic G1-G1/S phases R-HSA-2559585: Oncogene Induced Senescence R-HSA-2559580: Oxidative Stress Induced Senescence R-HSA-597592: Post-translational protein modification R-HSA-5633007: Regulation of TP53 Activity R-HSA-6804757: Regulation of TP53 Degradation R-HSA-6806003: Regulation of TP53 Expression and Degradation R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins R-HSA-2990846: SUMOylation R-HSA-3108214: SUMOylation of DNA damage response and repair proteins R-HSA-3232118: SUMOylation of transcription factors R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP) R-HSA-3700989: Transcriptional Regulation by TP53 |
Summary | |
---|---|
Symbol | CDKN2A |
Name | cyclin-dependent kinase inhibitor 2A |
Aliases | p16; INK4a; CMM2; ARF; INK4; p16INK4a; p19Arf; p14ARF; cyclin-dependent kinase inhibitor 2A (melanoma, p16, ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CDKN2A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between CDKN2A and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | CDKN2A |
Name | cyclin-dependent kinase inhibitor 2A |
Aliases | p16; INK4a; CMM2; ARF; INK4; p16INK4a; p19Arf; p14ARF; cyclin-dependent kinase inhibitor 2A (melanoma, p16, ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CDKN2A in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CDKN2A |
Name | cyclin-dependent kinase inhibitor 2A |
Aliases | p16; INK4a; CMM2; ARF; INK4; p16INK4a; p19Arf; p14ARF; cyclin-dependent kinase inhibitor 2A (melanoma, p16, ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CDKN2A in various data sets.
|
Points in the above scatter plot represent the mutation difference of CDKN2A in various data sets.
|
Summary | |
---|---|
Symbol | CDKN2A |
Name | cyclin-dependent kinase inhibitor 2A |
Aliases | p16; INK4a; CMM2; ARF; INK4; p16INK4a; p19Arf; p14ARF; cyclin-dependent kinase inhibitor 2A (melanoma, p16, ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDKN2A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CDKN2A |
Name | cyclin-dependent kinase inhibitor 2A |
Aliases | p16; INK4a; CMM2; ARF; INK4; p16INK4a; p19Arf; p14ARF; cyclin-dependent kinase inhibitor 2A (melanoma, p16, ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDKN2A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDKN2A. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CDKN2A |
Name | cyclin-dependent kinase inhibitor 2A |
Aliases | p16; INK4a; CMM2; ARF; INK4; p16INK4a; p19Arf; p14ARF; cyclin-dependent kinase inhibitor 2A (melanoma, p16, ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDKN2A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CDKN2A |
Name | cyclin-dependent kinase inhibitor 2A |
Aliases | p16; INK4a; CMM2; ARF; INK4; p16INK4a; p19Arf; p14ARF; cyclin-dependent kinase inhibitor 2A (melanoma, p16, ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CDKN2A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CDKN2A |
Name | cyclin-dependent kinase inhibitor 2A |
Aliases | p16; INK4a; CMM2; ARF; INK4; p16INK4a; p19Arf; p14ARF; cyclin-dependent kinase inhibitor 2A (melanoma, p16, ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CDKN2A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CDKN2A |
Name | cyclin-dependent kinase inhibitor 2A |
Aliases | p16; INK4a; CMM2; ARF; INK4; p16INK4a; p19Arf; p14ARF; cyclin-dependent kinase inhibitor 2A (melanoma, p16, ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CDKN2A collected from DrugBank database. |
There is no record. |